Adamas drug to help MS patients walk does not show expected clinical benefit

Adamas Pharmaceuticals Inc said on Tuesday its drug to treat walking impairment in patients with multiple sclerosis did not show the clinical benefit the drugmaker was hoping for in a late-stage trial.